UY27522A1 - PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS - Google Patents
PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERSInfo
- Publication number
- UY27522A1 UY27522A1 UY27522A UY27522A UY27522A1 UY 27522 A1 UY27522 A1 UY 27522A1 UY 27522 A UY27522 A UY 27522A UY 27522 A UY27522 A UY 27522A UY 27522 A1 UY27522 A1 UY 27522A1
- Authority
- UY
- Uruguay
- Prior art keywords
- alkyl
- optionally substituted
- treatment
- pde9 inhibitors
- cardiovascular disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a los inhibidores PDE9 para el tratamiento de trastornos cardiovasculares. Los inhibidores PDE9 preferidos son compuestos de la fórmula I en los que R1 es H o alquilo C1-6, en el que R1 está unido bien a N1 o N2, R2 es alquilo C1-6 opcionalmente sustituido con hidroxi o alcoxi; cicloalquilo C3-7 opcionalmente sustituido con alquilo, hidroxi, o alcoxi; un heterociclo saturado de 5-6 miembros opcionalmente sustituido con alquilo, hidroxi o alcoxi, het1 o Ar1, R3 es al quilo C1-6 opcionalmente sustituido con 1 o 2 grupos independientemente seleccionados entre: Ar2, cicloalquilo C3-7 opcionalmente sustiuido con alquilo C1-6; OAr2; SAr2; NHC(O) alquilo C1-6; het2; xanteno; naftaleno.The invention relates to PDE9 inhibitors for the treatment of cardiovascular disorders. Preferred PDE9 inhibitors are compounds of the formula I in which R1 is H or C1-6 alkyl, wherein R1 is bonded either to N1 or N2, R2 is C1-6 alkyl optionally substituted with hydroxy or alkoxy; C3-7 cycloalkyl optionally substituted with alkyl, hydroxy, or alkoxy; a saturated 5-6 membered heterocycle optionally substituted with alkyl, hydroxy or alkoxy, het1 or Ar1, R3 is C1-6 alkyl optionally substituted with 1 or 2 groups independently selected from: Ar2, C3-7 cycloalkyl optionally substituted with C1 alkyl -6; OAr2; SAr2; NHC (O) C1-6 alkyl; het2; xanthene; naphthalene
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0126395A GB0126395D0 (en) | 2001-11-02 | 2001-11-02 | Pyrazolo[4,3]pyrimidine derivatives and their use in treating disease |
GB0130695A GB0130695D0 (en) | 2001-12-21 | 2001-12-21 | Pyrazola[4,3]pyrimidine |
GB0216761A GB0216761D0 (en) | 2002-07-18 | 2002-07-18 | PDE9 Inhibitors for treating cardiovascular disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27522A1 true UY27522A1 (en) | 2003-06-30 |
Family
ID=27256310
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27522A UY27522A1 (en) | 2001-11-02 | 2002-10-30 | PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1440073A1 (en) |
JP (1) | JP2005511575A (en) |
AR (1) | AR037329A1 (en) |
BR (1) | BR0214096A (en) |
CA (1) | CA2466824A1 (en) |
DO (1) | DOP2002000482A (en) |
HN (1) | HN2002000317A (en) |
MX (1) | MXPA04004171A (en) |
PA (1) | PA8557401A1 (en) |
PE (1) | PE20030702A1 (en) |
SV (1) | SV2004001373A (en) |
TW (1) | TW200300081A (en) |
UY (1) | UY27522A1 (en) |
WO (1) | WO2003037899A1 (en) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2459161A1 (en) | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain |
US7262187B2 (en) | 2001-12-06 | 2007-08-28 | Merck & Co., Inc. | Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor |
DE10238722A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Improving attention, concentration, cognition, learning and/or memory performance, using selective phosphodiesterase 9A inhibitors, preferably 4H-pyrazolo-(3,4-d)-pyrimidin-4-one derivatives |
DE10238723A1 (en) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl substituted pyrazolyprimidines |
DE10238724A1 (en) | 2002-08-23 | 2004-03-04 | Bayer Ag | New 6-alkyl-1,5-dihydro-4H-pyrazolo-(3,4-d)-pyrimidin-4-ones useful as selective phosphodiesterase 9A inhibitors for improving attention, concentration, learning and/or memory performance |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
AU2004235915B2 (en) * | 2003-05-09 | 2010-08-05 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines |
US8044060B2 (en) | 2003-05-09 | 2011-10-25 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory |
DE10320785A1 (en) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-arylmethyl substituted pyrazolopyrimidines |
DE102004004142A1 (en) * | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines |
DE10328479A1 (en) * | 2003-06-25 | 2005-01-13 | Bayer Ag | 6-arylamino-5-cyano-4-pyrimidinones |
NZ544756A (en) | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
DE102004001873A1 (en) | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Method of treating men with metabolic and anthropometric disorders |
US7067659B2 (en) * | 2004-04-23 | 2006-06-27 | Duke University | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof |
AR054425A1 (en) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO. |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
DE102005024494A1 (en) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Use of cyanopyrimidines |
JP5140418B2 (en) | 2005-06-14 | 2013-02-06 | あすか製薬株式会社 | Thienopyrimidine derivatives |
EP1919287A4 (en) * | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | Organic compounds for treating reduced dopamine receptor signalling activity |
KR20090042227A (en) | 2006-06-06 | 2009-04-29 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | Organic compounds |
JP5193866B2 (en) * | 2006-08-08 | 2013-05-08 | あすか製薬株式会社 | Quinazoline derivatives |
ES2566774T3 (en) | 2006-12-13 | 2016-04-15 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivative |
AU2007332439A1 (en) * | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | Therapeutic agent for urinary tract disease |
US8383852B2 (en) * | 2007-02-16 | 2013-02-26 | Emisphere Technologies, Inc. | Compounds having a cyclic moiety and compositions for delivering active agents |
GEP20125405B (en) * | 2007-05-11 | 2012-02-27 | Pfizer | Amino-heterocyclic compounds |
JP5498392B2 (en) * | 2007-11-30 | 2014-05-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 1,5-Dihydro-pyrazolo [3,4-D] pyrimidin-4-one derivatives and their use as PDE9A modulators for the treatment of CNS disorders |
WO2009073210A1 (en) | 2007-12-06 | 2009-06-11 | Intra-Cellular Therapies, Inc | Organic compounds |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
EP2334684B1 (en) | 2008-09-08 | 2017-08-02 | Boehringer Ingelheim International GmbH | Pyrazolopyrimidines and their use for the treatment of cns disorders |
CN102264228A (en) | 2008-10-22 | 2011-11-30 | 默沙东公司 | Novel cyclic benzimidazole derivatives useful for anti-diabetic agents |
CN102271509A (en) | 2008-10-31 | 2011-12-07 | 默沙东公司 | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
CA2740385A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN102223799A (en) | 2008-12-06 | 2011-10-19 | 细胞内治疗公司 | Organic compounds |
EA201170772A1 (en) | 2008-12-06 | 2012-03-30 | Интра-Селлулар Терапиз, Инк. | ORGANIC COMPOUNDS |
TWI404721B (en) | 2009-01-26 | 2013-08-11 | Pfizer | Amino-heterocyclic compounds |
AU2010219598A1 (en) * | 2009-03-05 | 2011-09-22 | Astellas Pharma Inc. | Quinoxaline compounds |
DK2414363T3 (en) | 2009-03-31 | 2014-01-27 | Boehringer Ingelheim Int | 1-heterocyclyl-1,5-dihydro-pyrazole [3,4-d] pyrimidin-4-one derivatives and their use as PDE9A modulators. |
WO2011016861A2 (en) | 2009-08-05 | 2011-02-10 | Intra-Cellular Therapies, Inc. | Novel regulatory proteins and inhibitors |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011153136A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2590657A4 (en) | 2010-05-31 | 2014-02-12 | Intra Cellular Therapies Inc | Organic compounds |
WO2012004900A1 (en) * | 2010-07-09 | 2012-01-12 | Aska Pharmaceutical Co., Ltd. | Thienopyrimidine compounds |
SG187081A1 (en) | 2010-08-12 | 2013-03-28 | Boehringer Ingelheim Int | 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
CA2810696C (en) | 2010-09-07 | 2018-09-18 | Astellas Pharma Inc. | Pyrazoloquinoline compound |
WO2012033101A1 (en) | 2010-09-07 | 2012-03-15 | アステラス製薬株式会社 | Quinoxaline compound |
US8637536B2 (en) * | 2010-12-06 | 2014-01-28 | Glaxo Group Limited | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
CN103476258B (en) | 2011-02-25 | 2017-04-26 | 默沙东公司 | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
MX370433B (en) * | 2011-10-10 | 2019-12-13 | H Lundbeck As | Pde9i with imidazo pyrazinone backbone. |
US9434733B2 (en) | 2012-01-26 | 2016-09-06 | H. Lundbeck A/S | PDE9 inhibitors with imidazo triazinone backbone |
JP2015525782A (en) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN102786525B (en) | 2012-08-08 | 2014-12-17 | 中山大学 | N-substituted pyrazolo [3, 4-d] pyrimidine ketone compound and preparation method and application thereof |
MX2015010935A (en) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Antidiabetic bicyclic compounds. |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
DK3865484T3 (en) | 2015-07-07 | 2024-01-29 | H Lundbeck As | PDE9 INHIBITOR WITH IMIDAZOPYRAZINONE BACKBONE FOR THE TREATMENT OF PERIPHERAL DISEASES |
US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
AU2018276565A1 (en) | 2017-06-01 | 2019-11-07 | Eisai R&D Management Co., Ltd. | Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil |
JP7269875B2 (en) | 2017-06-01 | 2023-05-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Lewy Body Disease Treatment Agent Containing Pyrazoloquinoline Derivative |
IL270394B (en) | 2017-06-01 | 2022-08-01 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
KR20200010211A (en) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pharmaceutical composition comprising a PDE9 inhibitor |
AU2019275075A1 (en) | 2018-05-25 | 2021-01-14 | Cardurion Pharmaceuticals, Inc. | Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7H-imid azo [1,5- a] pyrazin-8-one |
BR112021003686A2 (en) * | 2018-08-31 | 2021-05-18 | Imara Inc. | pde9 inhibitors to treat sickle cell disease |
WO2020182076A1 (en) * | 2019-03-08 | 2020-09-17 | 南京药捷安康生物科技有限公司 | Uses of phosphodiesterase inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3939161A (en) * | 1973-10-29 | 1976-02-17 | Abbott Laboratories | 1,3-Dimethyl- 1H-pyrazolo(4,3-D) pyrimidine-7 (6H)-ones |
US4666908A (en) * | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
GB9722520D0 (en) * | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
DE19838705A1 (en) * | 1998-08-26 | 2000-03-02 | Bayer Ag | New dihydro- (1,2,3) -triazolo- [4,5-d] pyrimidin-7-ones |
IL139456A0 (en) * | 1999-11-08 | 2001-11-25 | Pfizer | Compounds for the treatment of female sexual dysfunction |
JP2004534733A (en) * | 2001-02-05 | 2004-11-18 | ドクター・レディーズ・ラボラトリーズ・リミテッド | Aryl-substituted alkyl carboxylic acids as blood cholesterol lowering agents |
-
2002
- 2002-10-01 HN HN2002000317A patent/HN2002000317A/en unknown
- 2002-10-09 DO DO2002000482A patent/DOP2002000482A/en unknown
- 2002-10-22 WO PCT/IB2002/004385 patent/WO2003037899A1/en not_active Application Discontinuation
- 2002-10-22 BR BR0214096-9A patent/BR0214096A/en not_active IP Right Cessation
- 2002-10-22 EP EP02777623A patent/EP1440073A1/en not_active Withdrawn
- 2002-10-22 MX MXPA04004171A patent/MXPA04004171A/en unknown
- 2002-10-22 CA CA002466824A patent/CA2466824A1/en not_active Abandoned
- 2002-10-22 JP JP2003540180A patent/JP2005511575A/en active Pending
- 2002-10-29 PA PA20028557401A patent/PA8557401A1/en unknown
- 2002-10-30 UY UY27522A patent/UY27522A1/en not_active Application Discontinuation
- 2002-10-30 PE PE2002001070A patent/PE20030702A1/en not_active Application Discontinuation
- 2002-10-31 AR ARP020104152A patent/AR037329A1/en unknown
- 2002-11-01 TW TW091132424A patent/TW200300081A/en unknown
- 2002-11-01 SV SV2002001373A patent/SV2004001373A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HN2002000317A (en) | 2003-05-21 |
EP1440073A1 (en) | 2004-07-28 |
PE20030702A1 (en) | 2003-08-21 |
DOP2002000482A (en) | 2003-05-31 |
SV2004001373A (en) | 2004-01-07 |
BR0214096A (en) | 2004-09-28 |
JP2005511575A (en) | 2005-04-28 |
WO2003037899A1 (en) | 2003-05-08 |
MXPA04004171A (en) | 2004-09-06 |
PA8557401A1 (en) | 2003-11-12 |
AR037329A1 (en) | 2004-11-03 |
TW200300081A (en) | 2003-05-16 |
CA2466824A1 (en) | 2003-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27522A1 (en) | PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | |
NO20041493L (en) | Chemical connections. | |
CY1106247T1 (en) | THIOPHEN- AND THIAZOLESULFONAMIDES AS ANTINEOPLASTIC AGENTS | |
NO20031001L (en) | Polyarylcarboxamides useful as lipid-lowering agents | |
UY28513A1 (en) | NEW COMPOUNDS | |
AR063706A1 (en) | CERTAIN AMIDAS REPLACED, THE USE OF THE SAME FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE ACTIVITY OF BTK AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. | |
AR045595A1 (en) | USEFUL COMPOSITIONS AS INHIBITORS OF KINASE PROTEINS | |
UY28514A1 (en) | NEW COMPOUNDS | |
ECSP109932A (en) | SUBSTITUTED BICYCOLACTAMA COMPOUNDS | |
AR030893A1 (en) | COMBINED USE OF GABAA ACETILCOLINESTERASE INHIBITORS AND INVESTED AGONISTS FOR THE TREATMENT OF COGNITIVE DISORDERS | |
SE0303180D0 (en) | Novel compounds | |
UY28877A1 (en) | METHYL-ARIL OR HETEROARIL-AMIDA SUBSTITUTED COMPOUNDS AND COMPOSITIONS | |
GT200600134A (en) | NEW COMPOUNDS OF AMINOSULPHONYL DERIVATIVES | |
AR016523A1 (en) | INDOL COMPOUNDS AS ANTI-INFLAMMATORY / ANALGESIC AGENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND TREATMENT PROCEDURE | |
EA200801608A1 (en) | DERIVATIVES OF BENZIMIDAZOLONIC CARBONIC ACID | |
DOP2001000205A (en) | DERIVATIVES OF CYCLOPENTIL-GLUTARAMIDE AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | |
NI201000049A (en) | METHOD TO PRODUCE 2'-DEOXY-5-AZACITIDINE (DECITABIN) | |
DE60214990D1 (en) | BENZOLSULFONIC ACID ESTERS INDOL-5-YL AS 5-HT6 RECEPTOR ANTAGONISTS | |
NO20050612L (en) | Pyrrolidine derivatives as oxytocin antagonists | |
ECSP024244A (en) | USE OF (Z) -2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID (4´-TRIFLUOROMETHYLPHENYL) -AMIDE FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
ATE411287T1 (en) | NEW METALPROTEINASE INHIBITORS | |
AR040763A1 (en) | PROFARMACOS OF THE (N-2- PIRIDIL-N-2- HYDROXICARBONIL-ETIL) - AMID OF THE ACID 1- METHYL-2- (4-AMIDINOPHENYLAMINOMETIL) - BENZIMIDAZOL-5-IL-CARBOXILICO, ITS PREPARATION AND ITS USE AS MEDICATIONS | |
CO5590858A2 (en) | FUNGICIDE COMPOSITION BASED ON A PYRIDILMETILBENZAMIDA AND IPROVALICARB DERIVATIVE | |
AR054414A1 (en) | ESPIRO-HYDANTOINE COMPOUNDS REPLACED WITH PIRIDILE. PHARMACEUTICAL COMPOSITIONS. | |
EA200800203A1 (en) | ISOMOTOPED INHIBITORS OF PROTON PUMP |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20141217 |